Tetra Bio-Pharma Inc. Guy Chamberland talks to Proactive about the significance of the response letter for a Type C meeting with the FDA for its inhaled cannabinoid-based product, QIXLEEF.
Chamberland says the FDA has given the group clear guidance, which will allow Tetra to refine its timeliness and budgets to advance and potentially commercialize QIXLEEF.
source
